Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 17:13:1010147.
doi: 10.3389/fneur.2022.1010147. eCollection 2022.

Machine learning can predict mild cognitive impairment in Parkinson's disease

Affiliations

Machine learning can predict mild cognitive impairment in Parkinson's disease

Marianna Amboni et al. Front Neurol. .

Abstract

Background: Clinical markers of cognitive decline in Parkinson's disease (PD) encompass several mental non-motor symptoms such as hallucinations, apathy, anxiety, and depression. Furthermore, freezing of gait (FOG) and specific gait alterations have been associated with cognitive dysfunction in PD. Finally, although low cerebrospinal fluid levels of amyloid-β42 have been found to predict cognitive decline in PD, hitherto PET imaging of amyloid-β (Aβ) failed to consistently demonstrate the association between Aβ plaques deposition and mild cognitive impairment in PD (PD-MCI).

Aim: Finding significant features associated with PD-MCI through a machine learning approach.

Patients and methods: Patients were assessed with an extensive clinical and neuropsychological examination. Clinical evaluation included the assessment of mental non-motor symptoms and FOG using the specific items of the MDS-UPDRS I and II. Based on the neuropsychological examination, patients were classified as subjects without and with MCI (noPD-MCI, PD-MCI). All patients were evaluated using a motion analysis system. A subgroup of PD patients also underwent amyloid PET imaging. PD-MCI and noPD-MCI subjects were compared with a univariate statistical analysis on demographic data, clinical features, gait analysis variables, and amyloid PET data. Then, machine learning analysis was performed two times: Model 1 was implemented with age, clinical variables (hallucinations/psychosis, depression, anxiety, apathy, sleep problems, FOG), and gait features, while Model 2, including only the subgroup performing PET, was implemented with PET variables combined with the top five features of the former model.

Results: Seventy-five PD patients were enrolled (33 PD-MCI and 42 noPD-MCI). PD-MCI vs. noPD-MCI resulted in older and showed worse gait patterns, mainly characterized by increased dynamic instability and reduced step length; when comparing amyloid PET data, the two groups did not differ. Regarding the machine learning analyses, evaluation metrics were satisfactory for Model 1 overcoming 80% for accuracy and specificity, whereas they were disappointing for Model 2.

Conclusions: This study demonstrates that machine learning implemented with specific clinical features and gait variables exhibits high accuracy in predicting PD-MCI, whereas amyloid PET imaging is not able to increase prediction. Additionally, our results prompt that a data mining approach on certain gait parameters might represent a reliable surrogate biomarker of PD-MCI.

Keywords: Parkinson's disease; amyloid PET imaging; gait analysis; machine learning; mild cognitive impairment.

PubMed Disclaimer

Conflict of interest statement

Unrelated to this study, PB received consultancies as a member of the advisory board for Zambon, Lundbeck, UCB, Chiesi, Abbvie, and Acorda; RE received consultancies from Zambon and honoraria from TEVA. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Receiver Operating Characteristic (ROC) curve of SVM algorithm (blue line); ROC = 0.5, threshold for considering the model better than random guessing (black line). P(MCI 1/0 = 1) (orange line) is the probability of the model correctly classifying group 1, which corresponds to PD-MCI patients.
Figure 2
Figure 2
Level of agreement among classifiers' scores for each model of the analysis.

References

    1. Baiano C, Barone P, Trojano L, Santangelo G. Prevalence and clinical aspects of mild cognitive impairment in Parkinson's disease: A meta-analysis. Mov Disord. (2020) 35:45–54. 10.1002/mds.27902 - DOI - PubMed
    1. Hoogland J, Boel JA, de Bie RMA, Geskus RB, Schmand BA, Dalrymple-Alford JC, et al. . Mild cognitive impairment as a risk factor for Parkinson's disease dementia. Mov Disord. (2017) 32:1056–65. 10.1002/mds.27002 - DOI - PubMed
    1. Saredakis D, Collins-Praino LE, Gutteridge DS, Stephan BCM, Keage HAD. Conversion to MCI and dementia in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. (2019) 65:20–31. 10.1016/j.parkreldis.2019.04.020 - DOI - PubMed
    1. Jellinger KA. Morphological basis of Parkinson disease-associated cognitive impairment: an update. J Neural Transm (Vienna). (2022) 129:977–99. 10.1007/s00702-022-02522-4 - DOI - PubMed
    1. Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. . Cognitive decline in Parkinson disease. Nat Rev Neurol. (2017) 13:217–31. 10.1038/nrneurol.2017.27 - DOI - PMC - PubMed